Dassault Systèmes has completed its acquisition of Medidata Solutions, which will now operate as a Dassault Systèmes brand powered by the 3DEXPERIENCE platform.
The 3DEXPERIENCE platform is a business experience platform which exists to manage the design, production and support of products across multiple industries.
Connecting 3DEXPERIENCE with Medidata’s Clinical Trial platform will help clinicians connect the dots between research, development, manufacturing, clinical trials and commercial deployment throughout the health ecosystem.
Through 3DEXPERIENCE, product developers can create a digital twin of the product they are working on, through which they can measure and assess its metrics. This can be used to predict the performance of the asset and help optimise its performance – for example, a medical device manufacturer could use the platform to perform a digital trial-run of a new hip replacement it had developed.
Dassault Systèmes vice chairman and CEO Bernard Charlès said: “Medidata will be a core brand in our information intelligence domain. By combining data intelligence and simulation, we power smarter therapeutics for healthier people.
“The virtual world will push the bounds of possibilities to transform not only research and science, but also the entire pharmaceutical and medical device industry and medicine, in general. We made virtual twins of cars and airplanes possible. We will do the same for the human body.”
Dassault Systèmes acquired all of the issued and outstanding common shares of Medidata for $92.25 per share in cash, representing a total value of approximately $5.8bn.
Medidata ceased trading on NASDAQ as of the close of trading on Monday 28 October 2019.
Medidata co-founder, chairman and CEO Tarek Sherif said: “With the combination of Dassault Systèmes and Medidata, we have never been in a stronger position to fulfill our ambition to bring the right treatment to the right patient at the right time.”